Thursday, July 26, 2018

Zavante Therapeutics Acquired By Nabriva Therapeutics

San Diego-based Zavante Therapeutics, a biopharmaceuticals firm developing injectable antibiotics for multi-drug resistant bacteria, has been acquired by Nabriva Therapeutics. According to Nabriva, it will pay 8.2 million shares of its stock, plus up to $97.5M based on future milestones, for Zavante Therapeutics. The deal is worth approximately $124M. Zavante Therapeutics was venture backed by Frazier Healthcare Partners, Longitude Capital, and Aisling Capital.